Eli Lilly predicts 30% higher sales

US pharmaceutical company Eli Lilly estimates sales in Romania will reach $30 million by the end of the year, up 30% from last year. “Eli Lilly’s plans for the near future do not include opening new production lines, but focusing on partnerships with local producers,” said Radu Rasinar, marketing manager of Eli Lilly for operations in Romania and Bulgaria. The company’s turnover for the first nine months of the year came to more than $20 million, Rasinar said. “The upward trend will maintain next year as well, when we expect our business to grow by 30%,” he added. Eli Lilly’s market share after nine months was 3%, ranking it tenth among pharmaceutical companies in Romania, according to Cegedim surveys. ZF